SCHEMBL14770731

SCHEMBL14770731

CCOc1ccc2[nH]c(C(OC(C)C)c3ccc(OC)cc3)nc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.49
HTT P42858 1/20 0.49
KMT2A Q03164 1/20 0.49
MLKL Q8NB16 2/20 0.39
HPGD P15428 3/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
CYP11B1 P15538 1/20 0.37
CYP11B2 P19099 1/20 0.37
CYP1A2 P05177 3/20 0.36
CYP2E1 P05181 3/20 0.36
CYP3A4 P08684 3/20 0.36
CYP2C8 P10632 3/20 0.36
CYP2D6 P10635 3/20 0.36
CYP2C9 P11712 3/20 0.36
CYP2B6 P20813 3/20 0.36
CYP2C19 P33261 3/20 0.36
MAPT P10636 2/20 0.36
HSD17B10 Q99714 2/20 0.36
ALDH1A1 P00352 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14770730 0.91 MLKL (0.44) MEN1HTTKMT2AMLKLHPGD
SCHEMBL14770535 0.88 MEN1 (0.53) MEN1HTTKMT2AHPGDNPC1
SCHEMBL12065627 0.87 MEN1 (0.46) MEN1HTTKMT2AMLKLHPGD
SCHEMBL12066053 0.84 MLKL (0.41) MEN1KMT2AMLKLHPGDNPC1
SCHEMBL14770471 0.82 MEN1 (0.55) MEN1HTTKMT2AMLKLHPGD
SCHEMBL12066021 0.82 MEN1 (0.42) MEN1HTTKMT2AMLKLNPC1
SCHEMBL12065289 0.81 CACNA1C (0.46) MEN1HTTKMT2AMLKLHPGD
SCHEMBL12065643 0.81 SCN10A (0.46) MLKLHPGDCYP1A2CYP2E1CYP3A4
SCHEMBL14770686 0.81 MLKL (0.60) MEN1HTTKMT2AMLKLNPC1
SCHEMBL14762610 0.79 HTT (0.42) MEN1HTTKMT2AMLKLNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096531-B2 Fused imidazole derivative TOA EIYO LTD. (JP) 2015-08-04 US disclosed
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE TOA EIYO LTD. (JP) 2013-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE CACNA1E, CACNA1G, CACNA1A MEN1 2676/4885HTT 3959/4885KMT2A 4545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.